NMN Under EFSA Review: What the Latest Evaluation Means for the Future of Nicotinamide Mononucleotide in Europe

What Is NMN and Why Is It Gaining So Much Attention?

In the world of nutritional science and longevity research, β-nicotinamide mononucleotide (NMN) has emerged as a standout compound. Known as a direct precursor to nicotinamide adenine dinucleotide (NAD⁺)—a molecule essential for energy metabolism, DNA repair, and cellular function—NMN is gaining traction for its potential in supporting healthy aging, vitality, and cognitive health.

Its appeal spans across health-conscious consumers, biohackers, and anti-aging researchers alike. As a result, the global NMN supplement market has witnessed steady growth over recent years.

However, in the European Union, the regulatory status of NMN has been somewhat unclear—until now.

EFSA’s Recent Action: NMN Officially Under Evaluation as a Novel Food

On July 25, 2025, the European Food Safety Authority (EFSA) published a public consultation document (PC-1537), officially announcing the safety assessment of β-nicotinamide mononucleotide (NMN) as a novel food under Regulation (EU) 2015/2283.

  • Applicant: Shanghai Shangke Biotechnology Co., Ltd. (China)
  • Regulatory Process: Novel food evaluation for dietary supplement use
  • Current Status: Safety evaluation under way; public consultation open

This move represents a significant milestone for brands and formulators in the EU. It means that NMN is now formally being considered for legal use in food supplements, pending EFSA’s safety review and eventual European Commission authorization.

Why EFSA’s Involvement Matters

EFSA’s role is crucial because any food ingredient not commonly consumed before May 1997 must be assessed under the EU Novel Food Regulation before entering the European market legally.

A positive EFSA opinion could open the door for:

  • Nutraceutical companies developing longevity and anti-aging formulations
  • Brands expanding into energy metabolism, mitochondrial health, or brain support
  • Distributors seeking EU-compliant, high-demand ingredients

If approved, NMN would join other novel compounds like Nicotinamide Riboside (NR) and CoQ10 that have carved out significant niches in the healthy aging supplement space.

NMN and NAD⁺: Scientific Overview

To understand the value of NMN, it’s important to look at how it works in the body.

NMN is a precursor to NAD⁺, a molecule required by nearly every cell for:

  • Energy metabolism
  • DNA damage repair
  • Cellular stress resistance
  • Gene expression through sirtuins

As we age, NAD⁺ levels decline. This decline is associated with fatigue, cognitive decline, inflammation, and metabolic disorders. NMN supplementation is being researched for its ability to:

  • Restore NAD⁺ levels
  • Support cognitive health
  • Enhance physical energy and stamina
  • Promote metabolic balance

Several animal studies and small human trials have shown promising results, although more robust clinical evidence is still under way.

What This Means for Brands and Product Developers

If you are a brand owner, product formulator, or private label business, here are key takeaways from EFSA’s review:

1. Timing Is Everything

EFSA’s review process typically takes 9 to 18 months. Brands that prepare early will be ready to launch compliant NMN products once approval is granted.

2. Compliance Starts with Quality

Work only with NMN suppliers who offer full traceability, safety testing, and regulatory documentation. This will ease your path toward future market authorization.

3. Demand Is Already There

Despite regulatory limitations, consumer demand for NMN is strong and growing. Early adopters in other markets (U.S., Asia) are already capitalizing on this trend.

E-Hiker Nutrition’s NMN: Ready to Support Your Growth

At E-Hiker Nutrition GmbH, we offer premium-grade NMN designed for innovation-ready brands preparing for compliant entry into the EU market.

Product Details:

  • Ingredient: β-Nicotinamide Mononucleotide (NMN)
  • Purity: 99% by HPLC
  • Origin: Produced by certified manufacturers (GMP, ISO)
  • Documentation: Full COA, MSDS, TDS, and technical dossier
  • Applications: Capsules, tablets, sachets, powders

Services We Offer:

  • OEM and private label manufacturing
  • Technical support and formulation guidance
  • EU warehouse stock for faster and safer delivery
  • Regulatory documentation support

Next Steps for Innovation-Ready Brands

Now is the right time to:

  • Secure high-quality NMN from a trusted partner
  • Develop compliant formulations in anticipation of EFSA approval
  • Educate your market on NMN’s science and regulatory status
  • Consult with us on product development and private label solutions

E-Hiker Nutrition is ready to help you stay ahead of the curve in a fast-evolving market.

Final Thoughts

EFSA’s evaluation of NMN signals a major shift in the European nutraceutical landscape. With consumer demand accelerating and scientific evidence building, NMN is poised to become a cornerstone ingredient in the next generation of healthy aging and energy support products.

Brands that start preparing now — with the right partners and regulatory foresight — will be in a strong position to lead once the market opens.

Contact us today to request a sample or explore how NMN can power your next formulation.

E-Hiker Nutrition GmbH
Supplying the Future of Nutraceutical Innovation
https://e-hikeringredients.de/
Email: info@e-hikeringredients.de

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top